Santen Pharmaceutical Co Stock Price Prediction
| SNPHY Stock | USD 10.61 0.39 3.55% |
Oversold Vs Overbought
38
Oversold | Overbought |
Using Santen Pharmaceutical hype-based prediction, you can estimate the value of Santen Pharmaceutical Co from the perspective of Santen Pharmaceutical response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Santen Pharmaceutical to buy its pink sheet at a price that has no basis in reality. In that case, they are not buying Santen because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell pink sheets at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Santen Pharmaceutical after-hype prediction price | USD 10.61 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as pink sheet price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Santen |
Santen Pharmaceutical After-Hype Price Prediction Density Analysis
As far as predicting the price of Santen Pharmaceutical at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Santen Pharmaceutical or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Pink Sheet prices, such as prices of Santen Pharmaceutical, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Santen Pharmaceutical Estimiated After-Hype Price Volatility
In the context of predicting Santen Pharmaceutical's pink sheet value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Santen Pharmaceutical's historical news coverage. Santen Pharmaceutical's after-hype downside and upside margins for the prediction period are 7.28 and 13.94, respectively. We have considered Santen Pharmaceutical's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Santen Pharmaceutical is somewhat reliable at this time. Analysis and calculation of next after-hype price of Santen Pharmaceutical is based on 3 months time horizon.
Santen Pharmaceutical Pink Sheet Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Santen Pharmaceutical is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Santen Pharmaceutical backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Pink Sheet price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Santen Pharmaceutical, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.18 | 3.33 | 0.00 | 0.00 | 0 Events / Month | 4 Events / Month | Within a week |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
10.61 | 10.61 | 0.00 |
|
Santen Pharmaceutical Hype Timeline
Santen Pharmaceutical is at this time traded for 10.61. The entity stock is not elastic to its hype. The average elasticity to hype of competition is 0.0. Santen is forecasted not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is insignificant. The immediate return on the next news is forecasted to be very small, whereas the daily expected return is at this time at -0.18%. %. The volatility of related hype on Santen Pharmaceutical is about 16650.0%, with the expected price after the next announcement by competition of 10.61. The company has price-to-book ratio of 1.39. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Santen Pharmaceutical last dividend was issued on the 29th of September 2022. The entity had 2499:1000 split on the 2nd of April 2015. Assuming the 90 days horizon the next forecasted press release will be within a week. Check out Santen Pharmaceutical Basic Forecasting Models to cross-verify your projections.Santen Pharmaceutical Related Hype Analysis
Having access to credible news sources related to Santen Pharmaceutical's direct competition is more important than ever and may enhance your ability to predict Santen Pharmaceutical's future price movements. Getting to know how Santen Pharmaceutical's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Santen Pharmaceutical may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| SNY | Sanofi ADR | 0.29 | 9 per month | 0.00 | (0.29) | 1.37 | (1.85) | 7.81 | |
| BMY | Bristol Myers Squibb | (1.20) | 6 per month | 1.19 | 0.09 | 2.23 | (2.07) | 14.39 | |
| AZN | AstraZeneca PLC ADR | 0.48 | 5 per month | 0.00 | (0.34) | 1.28 | (3.18) | 8.50 | |
| GILD | Gilead Sciences | 0.69 | 8 per month | 1.02 | 0.1 | 2.17 | (1.82) | 10.80 | |
| NVS | Novartis AG ADR | (0.16) | 8 per month | 0.00 | (0.33) | 1.12 | (1.98) | 6.05 |
Santen Pharmaceutical Additional Predictive Modules
Most predictive techniques to examine Santen price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Santen using various technical indicators. When you analyze Santen charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Santen Pharmaceutical Predictive Indicators
The successful prediction of Santen Pharmaceutical stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Santen Pharmaceutical Co, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Santen Pharmaceutical based on analysis of Santen Pharmaceutical hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Santen Pharmaceutical's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Santen Pharmaceutical's related companies.
Story Coverage note for Santen Pharmaceutical
The number of cover stories for Santen Pharmaceutical depends on current market conditions and Santen Pharmaceutical's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Santen Pharmaceutical is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Santen Pharmaceutical's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Other Macroaxis Stories
Our audience includes start-ups and big corporations as well as marketing, public relation firms, and advertising agencies, including technology and finance journalists. Our platform and its news and story outlet are popular among finance students, amateur traders, self-guided investors, entrepreneurs, retirees and baby boomers, academic researchers, financial advisers, as well as professional money managers - a very diverse and influential demographic landscape united by one goal - build optimal investment portfolios
Story Categories
Currently Trending Categories
Santen Pharmaceutical Short Properties
Santen Pharmaceutical's future price predictability will typically decrease when Santen Pharmaceutical's long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Santen Pharmaceutical Co often depends not only on the future outlook of the potential Santen Pharmaceutical's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Santen Pharmaceutical's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 400.4 M | |
| Cash And Short Term Investments | 84.3 B |
Additional Tools for Santen Pink Sheet Analysis
When running Santen Pharmaceutical's price analysis, check to measure Santen Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Santen Pharmaceutical is operating at the current time. Most of Santen Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Santen Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Santen Pharmaceutical's price. Additionally, you may evaluate how the addition of Santen Pharmaceutical to your portfolios can decrease your overall portfolio volatility.